NOVEL GROUP A STREPTOCOCCUS HUMAN VACCINE CANDIDATES
新型 A 组链球菌人类疫苗候选者
基本信息
- 批准号:7283635
- 负责人:
- 金额:$ 70.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-08-01 至 2009-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntigensAreaArtsBiologyCell surfaceChildhoodDataDevelopmentDiseaseDrug IndustryGenomeGlomerulonephritisGoalsGram-Positive BacteriaGuanosine MonophosphateHealthHeart DiseasesHumanIndustry CollaboratorsInfectionInfectious Skin DiseasesInternationalInvasiveInvestigationMacacaMacaca fascicularisMethodsModelingMonkeysMusNecrotizing fasciitisNeisseria meningitidisOrganismOutcomePathogenesisPharyngitisPhasePhenocopyPopulation GroupProteinsResearchResearch DesignRheumatic FeverRheumatic Heart DiseaseScarlet FeverScreening procedureSerotypingSore ThroatStreptococcusStreptococcus pyogenesStreptococcus vaccineSyndromeTimeLineTonsillitisToxic Shock SyndromeToxicity TestsUnited StatesVaccine AntigenVaccinesbasedesignextracellularhuman diseasein vivomouse modelmultiple myeloma M Proteinnovelpathogenpre-clinicalresearch studyvaccinology
项目摘要
DESCRIPTION (provided by applicant):
This study is designed to identify one or more conserved group A Streptococcus (GAS) proteins suitable for use as a safe and efficacious human vaccine worldwide. The key goal of the proposed research is to use genome-wide methods of contemporary vaccinology to identify one or more conserved GAS proteins that will significantly protect monkeys from pharyngitis caused by challenge with a strain expressing a heterologous M protein serotype. A conservative estimated timeline is that by the end of the 5-year research period, the antigen(s) will be ready for detailed toxicity testing prior to beginning phase I human trials. The international investigative team composed of academic and pharmaceutical industry collaborators proposes the following line of research involving a "reverse vaccinology" strategy:
Aim 1: Use two mouse models of invasive GAS disease to confirm extensive preliminary data that novel candidate GAS antigens significantly protect immunized mice challenged with a GAS strain expressing a heterologous M protein serotype.
Aim 2: Determine if the proteins satisfying the mouse screen criteria described in aim (1) above are conserved in natural populations of GAS, expressed on the cell surface of genetically diverse GAS strains, and expressed in vivo during diverse types of human infections (pharyngitis, invasive infections, etc).
Aim 3: Use a recently-described monkey model that mimics human pharyngitis to determine if one or more of the candidate vaccine antigens we identify in aim (1) and (2) significantly protects against pharyngitis caused by a GAS strain expressing a heterologous M protein serotype.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James MALLORY Musser其他文献
James MALLORY Musser的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James MALLORY Musser', 18)}}的其他基金
Molecular basis of decreased susceptibility to beta-lactam antibiotics in Streptococcus pyogenes
化脓性链球菌对β-内酰胺类抗生素敏感性降低的分子基础
- 批准号:
10596614 - 财政年份:2022
- 资助金额:
$ 70.14万 - 项目类别:
Molecular basis of decreased susceptibility to beta-lactam antibiotics in Streptococcus pyogenes
化脓性链球菌对β-内酰胺类抗生素敏感性降低的分子基础
- 批准号:
10449481 - 财政年份:2022
- 资助金额:
$ 70.14万 - 项目类别:
Novel Determinants of Streptococcus Pyogenes Virulence and Protective Immunity in the Primate Oropharynx: A Genome-wide Strategy
灵长类口咽部化脓性链球菌毒力和保护性免疫的新决定因素:全基因组策略
- 批准号:
10387431 - 财政年份:2021
- 资助金额:
$ 70.14万 - 项目类别:
Determinants of Streptococcus pyogenes fitness in the female primate genital tract: A genome-wide analysis
雌性灵长类生殖道中化脓性链球菌适应性的决定因素:全基因组分析
- 批准号:
9805040 - 财政年份:2019
- 资助金额:
$ 70.14万 - 项目类别:
NOVEL GROUP A STREPTOCOCCUS HUMAN VACCINE CANDIDATES
新型 A 组链球菌人类疫苗候选者
- 批准号:
7113176 - 财政年份:2004
- 资助金额:
$ 70.14万 - 项目类别:
NOVEL GROUP A STREPTOCOCCUS HUMAN VACCINE CANDIDATES
新型 A 组链球菌人类疫苗候选者
- 批准号:
7493506 - 财政年份:2004
- 资助金额:
$ 70.14万 - 项目类别:
NOVEL GROUP A STREPTOCOCCUS HUMAN VACCINE CANDIDATES
新型 A 组链球菌人类疫苗候选者
- 批准号:
6931521 - 财政年份:2004
- 资助金额:
$ 70.14万 - 项目类别:
NOVEL GROUP A STREPTOCOCCUS HUMAN VACCINE CANDIDATES
新型 A 组链球菌人类疫苗候选者
- 批准号:
6804318 - 财政年份:2004
- 资助金额:
$ 70.14万 - 项目类别:
GENETIC EPIDEMIOLOGY OF TUBERCULOSIS SUSCEPTIBILITY
结核病易感性的遗传流行病学
- 批准号:
2672974 - 财政年份:1997
- 资助金额:
$ 70.14万 - 项目类别:
GENETIC EPIDEMIOLOGY OF TUBERCULOSIS SUSCEPTIBILITY
结核病易感性的遗传流行病学
- 批准号:
2005705 - 财政年份:1997
- 资助金额:
$ 70.14万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 70.14万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 70.14万 - 项目类别: